

ChinaAMC Return Securities Investment Fund
&
ChinaAMC Xinghua Mixed Securities Investment Fund
(the “Funds”)

NOTICE TO UNITHOLDERS

This notice is important and requires your immediate attention. If you are in any doubt about the contents of this notice, you should consult your bank manager, legal adviser, accountant or other independent financial adviser. China Asset Management Co., Ltd. (the “**Company**”), the Fund Manager of the Funds, accepts full responsibility for the accuracy of the information contained in this notice at the date of publication.

4 December 2021

Dear Unitholders,

Investment in Equity Underwritten by Connected Party of the Fund Manager

In accordance with the *Administrative Measures on the Operation of Publicly Offered Securities Investment Funds*, the *Administrative Measures on Information Disclosure of Publicly Offered Securities Investment Funds* and relevant laws and regulations, fund contracts and prospectus etc., after fulfilling the prescribed approval procedures and obtaining the approval from the fund custodian, the Funds under management of China Asset Management Co., Ltd. participated in the offline subscription of initial public offering of RMB ordinary shares (A shares) of Dizal (Jiangsu) Pharmaceutical Co., Ltd. (hereinafter referred to as “Dizal Pharmaceutical”).

CITIC Securities Co., Ltd., the controlling shareholder of the Company, is the sponsor (lead underwriter) of the particular issuance of Dizal Pharmaceutical. The issue price of Dizal Pharmaceutical is RMB 52.58 per share and it was negotiated and determined by the issuer and joint lead underwriter based on the consideration of factors such as preliminary inquiry results, comprehensive evaluation of aspects of reasonable investment value, valuation level of comparable companies in the secondary market, valuation level of the secondary market of the industry, thorough consideration of valid subscription ratio by offline investors, the market condition, fund-raising requirement and underwriting risks etc.

The relevant information of the Funds’ participation in the offline subscription of Dizal Pharmaceutical’s issuance is as follows:

	Name of Allocated Security	Allocated Number (No. of Shares)	Allocated Amount (RMB)
ChinaAMC Return Securities Investment Fund	Dizal Pharmaceutical	8,926	469,329.08

ChinaAMC Xinghua Mixed Securities Investment Fund	Dizal Pharmaceutical	8,926	469,329.08
---------------------------------------------------------	----------------------	-------	------------

Should you have any enquiries regarding the above, please contact the Hong Kong Representative at 37/F, Bank of China Tower, 1 Garden Road, Central, Hong Kong or the enquiry hotline at (852) 3406 8686 during office hours or by electronic mail at hkfund_services@chinaamc.com.

Yours faithfully,

China Asset Management Co., Ltd.